ArticleRheumatology international2016
Epidemiological study of adult-onset Still's disease using a Japanese administrative database.
Article in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Bibliometrics analysis on the research status and trends of adult-onset Still's disease: 1921-2021.Frontiers in immunology · 2022Pooled it
- Article
- Challenges on diagnosis and treatment of refractory adult-onset still disease in Sub-Saharan Africa: a case report.Journal of medical case reports · 2025Article
- Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025Article
- Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.Drugs & aging · 2024Review
- A Case of Macrophage Activation Syndrome With Elderly Onset Still's Disease Under Tocilizumab Treatment.Cureus · 2024Article
- Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.Clinical rheumatology · 2024Review
- Clinical characteristics and outcome of elderly onset adult-onset Still's disease: A 10-year retrospective study.Journal of translational autoimmunity · 2023Article
- Clinical features and serum cytokine profiles of elderly-onset adult-onset Still's disease.Scientific reports · 2022Article
- Adult-onset Still's disease in Western Australia: Epidemiology, comorbidity and long-term outcome.International journal of rheumatic diseases · 2022Article
- Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: A case report.Medicine · 2022Article
- Clinical characteristics and treatment of elderly onset adult-onset Still's disease.Scientific reports · 2022Article
- Latent class analysis of 216 patients with adult-onset Still's disease.Arthritis research & therapy · 2022Article
- Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.Frontiers in medicine · 2022Review
- Existing Data Sources for Clinical Epidemiology: Database of the National Hospital Organization in Japan.Clinical epidemiology · 2022Review
- Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.Journal of clinical medicine · 2021Article
- Elderly-onset adult Still's disease.Reumatologia · 2021Article
- Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.Rheumatology (Oxford, England) · 2020Article
- Elderly-onset Still's Disease Complicated by Macrophage Activation Syndrome: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2020Article
- Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) is a rare disease, and large epidemiological studies of this disease are limited. Furthermore, it has been difficult to show the incidence and characteristics of severe AOSD complications due to the rarity of this disease. The aim of our study was to describe the demographics of AOSD and the incidence and characteristics of severe complications. Using a large Japanese administrative database, we identified hospitalized patients with AOSD and described the demographics. We also calculated the incidence of severe complications (i.e., macrophage activation syndrome [MAS] and disseminated intravascular coagulation [DIC]) and in-hospital mortality in AOSD patients, and then analyzed the age-controlled difference between men and women. We identified 513 patients with AOSD (mean age: 53.1 years; women 64.1 %). According to the age distribution, there was no distinct peak age. The thirties and the sixties were relatively large age groups. There were 76 patients of AOSD with MAS or DIC observed in this study. The incidence of severe complications was 14.8 %, 95 % CI [11.9, 18.2]. Women were more likely to have severe complications than men after controlling for age (odds ratio: 2.07; [1.14, 3.73]; p = 0.014). AOSD does not predominantly affect young adults in our study population. Elderly AOSD patients can be observed more than before due to global population aging. Severe complications are more likely to occur in women than in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.